2nd International Conference on Cardiovascular Medicine and Cardiac Surgery

Mar 15-16, 2023

|

Chicago, United States of America



About Conference

The "2nd International Conference on Cardiovascular Medicine and Cardiac Surgery" will be held in Chicago, Illinois, on March 15–16, 2023. It will include brief keynote addresses, speaker talks, exhibitions, symposia, workshops, and speaker sessions. Cardiovascular Medicine 2023 encourages all attendees to attend.

Theme: “Latest Research of Cardiac Medicine and Surgical Tool”

The aim of Cardiovascular Medicine 2023 is to provide a revolutionary professional evolution experience that addresses the full spectrum of ongoing research in cardiovascular medicine and innovative technology for cardiac surgery.

To explore methods for treating heart diseases, electrocardiography, heart failure, pediatric cardiology, and other health issues, Cardiovascular Medicine 2023 will bring together top academics, scientists, researchers, physicians, students, percussionists, and cardiologists In order to aid professionals with problems affecting expectations and the search for recently found medications for the treatment of cardiac disease, we have intended to provide a variety of information.

Speakers at this conference are well-known and knowledgeable, covering both general and niche areas of interest. The main goals of our conference are to give cardiovascular doctors, cardiac surgeons, specialists, nurses, technologists, and anyone else professionally involved in cardiovascular disease and molecular cardiology an opportunity to learn about the evolution of the disease, talk about interventional procedures, gain knowledge of new and innovative cardiac surgery, practices, and their efficacy and efficiency in the treatment of various cases, and comprehend local realities.

The 1000+ Global Events handled by LexisConferences Conferences include 300+ Conferences, 500+ Upcoming and Past Symposiums, and Workshops in the USA, Europe, and Asia. LexisConferences Conferences also disseminates 700+ Open Access journals with more than 30000 recognizable figures, reputable experts, and article board members.

Target Audience

Associations and Societies of Cardiology |  Business Entrepreneurs Cardiac-Oncology & PharmacologyCardiac Surgeons Cardiologists Cardiology and Cardiac Nursing Associations |  Cardiology ImagingCardiology StudentsScientists  | Cardio-thoracic Surgeons |  CEOs of OrganizationsClinical EP & Internal Medicine |  Directors Echocardiography Emergency Medicine Endocrinology General Cardiology | Healthcare Industries |  Cardiology Manufacturing Companies |  Medicine Experts Paediatric & Preventive Cardiology Paediatric Cardiologists Paediatric Care Centres Professors, Associate Professors | Research Institutes |  Research Scholars Researcher Vascular Biologists

Participation Options and Benefits

We provide the participants with different modes or ways to participate as Delegate or Speaker under the ACADEMIC / STUDENT / BUSINESS Category. The mode of participation is webinar through PowerPoint Presentation/ Video Presentation.

  • Keynote speaker: 45-50 minutes
  • Speaker (oral presentation): 25-30 minutes (only one person can present)
  • Speaker (workshop): 45-50 minutes (more than 1 can present)
  • Speaker (special session): 45-50 minutes (more than 1 can present)
  • Speaker (symposium): more than 45 minutes (more than 1 can present)
  • Delegate(only registration): will have access to all the sessions with all the benefits of registration
  • Poster presenter:  can present a poster and enjoy the benefits of delegateRemote attendance:  can participate via video presentation or e-poster presentation
  • Exhibitor: can exhibit his/her company’s products by booking exhibitor booths of different sizes

 PARTICIPATION BENEFITS

  • Attend Keynote presentations by world’s most eminent researchers
  • Access to all the sessions
  • Get OCM certificate
  • Get worldwide acknowledgment to your profile and Research
  • Get your abstracts published with unique DOI in International Journals
  • Get up to 50% discounts for publishing your entire article in our open-access International Journals
  • Get Handbooks and conference kits
  • Get access to the network with eminent personalities from worldwide

Supporting Journals

All the selected Abstracts/ papers presented will be published in the Supporting Journals below:

       • Journal Name: Journal of Clinical & Experimental Cardiology

       • Journal Name:  Journal of Cardiovascular Diseases & Diagnosis

       • Journal Name: International Journal of Cardiovascular Research

Join our team Cardiovascular Medicine 2023 in this beautiful city of  Chicago and let us make this professional gathering a Great success.

Market Analysis

At a compound annual growth rate (CAGR) of 4.8%, the market for cardiovascular medications worldwide is anticipated to increase from $146.51 billion in 2021 to $153.60 billion in 2022. The companies' reorganization of operations and recovery from the COVID-19 impact, which had previously resulted in restrictive containment measures involving social estrangement, remote work, and the closure of commercial activities that created operational challenges, are primarily responsible for the growth. At a CAGR of 4%, the market is anticipated to reach $107.77 billion in 2025. The market for cerebral embolic protection devices is expected to develop at the quickest rate in the global cardiac surgery market, with a predicted value of approximately $14.2 billion in 2021. Despite COVID-19, it is anticipated that the size of the global market would rise throughout the projection period and surpass $20.4 billion by 2027.

Etiology, clinical characteristics, and therapy

Cardiomyopathies were the cause of heart failure in 28% of patients, followed by rheumatic heart disease in 12%, ischemic heart disease in 9%, and hypertension in 45% of patients. Other causes (like probable tuberculosis- or HIV-related cardiomyopathies, end myocardial fibrosis, and obstructive lung disease) accounted for 6% of the cases. Heart Failure caused by idiopathic dilated cardiomyopathy was the most common cardiomyopathy among those who had it (81%) and was followed by postpartum cardiomyopathy (15%). Hypertrophic and restrictive cardiomyopathies were uncommon (5 %). The most common valvular lesion was a rheumatic mitral disease with regurgitation (81%) followed by mitral stenosis (15%) and aortic regurgitation (3 %).

Importance and Scope

The greatest venue for scientists, cardiologists, oncologists, electro physiologists, surgeons, nurses, research scholars, and students working in this field to exchange knowledge about cardiology and cardiac surgery will be Cardiovascular Medicine 2023. An alternative to invasive imaging techniques against heart illnesses and heart failure problems in adults and children is being sought through this worldwide event.

Growth of the Cardiology Market

In 2022, the market size for cardiologists is predicted to grow by 2.6 percent. Between 2017 and 2022, the US Cardiologists market size increased by an average of 1.1 percent annually.

Statistics of Physicians, Researchers, and Academicians working on Cardiology Research

Directors, Heads, Deans, Professors, Scientists, Researchers, Doctors, Students, and Writers of the Pediatric Cardiology Department, as well as the Founders and Employees of Related Companies, Associations Members, Related Organizations, Laboratories Members, etc., make up the major portion of the world associated with the Cardiology field.

Inhibiting the progression of congestive heart failure through pharmacological, device-based therapies is a key objective of heart failure therapy. As a result, attempts have been made to create device-based therapies with the goal of enhancing cardiac reserve and increasing pump performance to satisfy metabolic requirements. Congestive heart failure frequently progresses more slowly due to additional factors that affect outcomes, such as new-onset arrhythmias, ischemia and infarction, valvulopathy, decompensation, end-organ damage, and therapeutic refractoriness. Sometimes, minor pathophysiologic changes presage the start of such illnesses, and prompt detection of these changes may encourage the adoption of preventative interventions. As a result, device-based approaches may play a crucial part in the prompt detection of the subtle pathophysiologic alterations linked to congestive heart failure in the future.

Related Companies/Industries

MEDNAX, Inc. | AstraZeneca | Sanofi | Boehringer Ingelheim | Roche |Bristol-Myers Squibb | United Therapeutics Astellas | Actelion | Takeda  |  Otsuka  | Gilead Sciences 

Related Associations and Societies

American Association of Heart Failure Nurses (AAHFN) | American Society of Nuclear Cardiology (ASNC) | American Society for Echocardiography | Pediatric Cardiology Associates.

Related Universities

University Maastricht | Academic Hospital Maastricht | Medical University of Graz | University of Debrecen Medical School | University of Nicosia Medical School Imperial College LondonJohns Hopkins University | Bukovina State Medical University |  Heidelberg University Hamburg University University of Lodz | Yale University North-western University Vanderbilt University University of Rochester

 

contact info:-

Program manager| Cardiovascular Medicine 2023

Email: [email protected]

Contact us: +44 (203) 966-4288,

What’s  App: +44- 7897073589

Program Overview